SCHEMBL2333467

SCHEMBL2333467

Nc1nc(C(=O)N2Cc3ccccc3C2)c2cc(-c3ccccc3S(=O)(=O)O)ccc2n1

nearest known ligand 0.71

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 11/20 0.71
HSP90AB1 P08238 3/20 0.64
F10 P00742 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 1/20 0.35
DHFR P00374 1/20 0.35
KDM4E B2RXH2 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
TRPV1 Q8NER1 1/20 0.34
MAPT P10636 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2329851 0.92 HSP90AA1 (0.71) HSP90AA1HSP90AB1F10TRPV1ALOX5AP
SCHEMBL13330307 0.91 HSP90AA1 (0.69) HSP90AA1HSP90AB1F10KDM4EHTT
SCHEMBL2329817 0.91 HSP90AA1 (0.69) HSP90AA1HSP90AB1F10SMN1; SMN2HPGD
SCHEMBL2510542 0.89 HSP90AA1 (0.64) HSP90AA1HSP90AB1SMN1; SMN2HPGDKDM4E
SCHEMBL2511442 0.89 HSP90AA1 (0.66) HSP90AA1HSP90AB1F10ALOX5APFEN1
SCHEMBL12199666 0.89 HSP90AA1 (0.66) HSP90AA1HSP90AB1F10ALOX5APFEN1
SCHEMBL2330286 0.88 HSP90AA1 (0.65) HSP90AA1HSP90AB1ALOX5APFEN1
SCHEMBL2512968 0.88 HSP90AA1 (0.65) HSP90AA1HSP90AB1ALOX5APFEN1
SCHEMBL2512041 0.87 HSP90AA1 (0.64) HSP90AA1HSP90AB1F10KDM4EHTT
SCHEMBL3097085 0.86 HSP90AA1 (0.63) HSP90AA1HSP90AB1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356110-B1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-01-06 EP disclosed
EP-2356110-B1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2016-01-06 EP disclosed
US-8546565-B2 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546565-B2 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546565-B2 Quinazolinamide derivatives MERCK PATENT GESELLSCHAFT (DE) 2013-10-01 US disclosed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 US disclosed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 US disclosed
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) 2011-10-06 US disclosed
EP-2356110-A1 QUINAZOLINAMIDE DERIVATIVES Merck Patent GmbH (DE) 2011-08-17 EP disclosed
WO-2010066324-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2010-06-17 WO disclosed
WO-2010066324-A1 QUINAZOLINAMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245225-A1 QUINAZOLINAMIDE DERIVATIVES HSP90AB1, HSP90AA1, HSP90B1 HSP90AA1 2/4885HSP90AB1 1/4885F10 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.